MiMedx Investors Get Initial OK For Fraud Deal, $3.5M In Fees

Law360 (October 9, 2020, 7:27 PM EDT) -- A Georgia federal judge has given preliminary approval to a derivative settlement that would require new controls at MiMedx Group Inc. and pay $3.5 million to plaintiffs' counsel to resolve shareholders' allegations that the biotech company's executives engaged in a yearslong scheme to inflate revenue. 

U.S. District Judge William M. Ray II gave the initial green light Thursday to settle a federal suit and two related shareholder derivative actions pending in Florida and Georgia state courts that alleged the executives amplified revenue in a so-called channel-stuffing scheme.

The derivative settlement requires MiMedx's board of directors to implement numerous corporate governance reforms to...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!